PPD wins 7-year HIV research contract

The pact will see PPD offer up research services for the fight against the infectious disease.

Major CRO player Pharmaceutical Product Development (PPD) has won a lucrative seven-year government contract in infectious disease.

The pact, financials details of which were not revealed, falls under the Clinical Research Support Services program of the Division of AIDS, National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.

Under the contract, PPD said it will “provide a broad range of clinical and other related research support services for the NIAID/DAIDS-supported clinical research portfolio and other infectious diseases relevant to HIV-infected and at-risk populations.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We are pleased to help NIAID develop and maintain a strong clinical infrastructure to meet the needs of DAIDS’ scientific agenda,” said William Sharbaugh, COO of the company.

RELATED: PPD to run first-in-human trial of Treos’ lead cancer vaccine

This latest agreement complements a long-standing collaboration between PPD and NIAID that, in March, was boosted to the middle of next decade, with PPD working on a "broad scope of research" in HIV.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

The Mayo Clinic tapped data analytics firm nference to build out an AI-powered engine to collate its years of clinical records and pathology work.

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.